23 results
Thumbnail

D1.257 - Hereditary Angioedema in Bulgaria (1972-2025): A Longitudinal Comparative Study of Trends in Diagnosis, Mortality, and the Impact of Modern Therapies

Thumbnail

D1.259 - Icatibant Use During Pregnancy: A South African Case Series

Thumbnail

D1.261 - Phenotypic and Immunological Profiles of Chronic Urticaria: A Cross- Sectional Study From South India

Thumbnail

D1.250 - Real-World Effectiveness and Safety of Icatibant for Hereditary Angioedema in China: An Interim Analysis of the EASTERN Study

Thumbnail

D1.253 - Probiotic Co-administration to Improve Gastrointestinal Tolerability of Berotralstat in Hereditary Angioedema: a multicenter case series from the ITACA network

Thumbnail

D1.254 - Comparison Between Classical and Updated Classifications in Patients Diagnosed with Isolated Angioedema: Finally, Did We Find the Ideal One?

Thumbnail

D1.255 - Is it Angioedema? Unmasking a complete Melkersson-Rosenthal Syndrome

Thumbnail

D1.256 - Chronic Inducible Urticaria in Real Life: A Single-Centre Retrospective Cohort

Thumbnail

D1.258 - First real-life experiences with Sebetralstat as oral on-demand treatment for acute HAE attacks documented in a global angioedema disease registry

Thumbnail

D1.260 - Clinical Characteristics and Hospitalization Patterns in Chronic Spontaneous Urticaria Patients in Bulgaria

Thumbnail

D2.19 - Can Drug Provocation Be Avoided in Low-Risk Quinolone Reactions?

Thumbnail

D2.17 - Diagnostic profitability of penicilloyl-polylysine and minor determinant mixture in urgent/preferred beta-lactam allergy studies in hospitalized patients from january 2023 to december 2025

Thumbnail

D2.20 - Selective Fixed Drug Eruption from Etoricoxib with Safe Celecoxib Use: Role of Patch Testing

Thumbnail

D2.21 - The Cyto-LTT: A multiplex cytokine assay to detect and assess the strength of T cell reactivity in drug hypersensitivity

Thumbnail

D2.29 - Use and knowledge of Phadiatop Infant and Fx5 in children from a primary care healthcare area

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis